Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial

B. Trolle; A. Flyvbjerg; U. Kesmodel; F.F. Lauszus
November 2007
Human Reproduction;Nov2007, Vol. 22 Issue 11, p2967
Academic Journal
BACKGROUND Our aim was to assess the effects of metformin on menstrual frequency, fasting plasma glucose (FPG), insulin resistance assessed as HOMA-index, weight, waist/hip ratio, blood pressure (BP), serum lipids, and testosterone levels in women with polycystic ovary syndrome (PCOS) METHODS In a randomized, controlled, double-blinded setup, 56 women aged 18–45 with PCOS were treated with either metformin 850 mg or placebo twice daily for 6 months. After a wash-out period of 3 months participants received the alternate treatment for 6 months. The changes in the measured parameters were analysed by intention-to-treat and per protocol RESULTS There were no changes in menstrual frequency. In the intention-to-treat analysis, weight and systolic BP were reduced on metformin treatment (p=0.009 and 0.047, respectively), while high-density lipoprotein (HDL) increased (p=0.001). On placebo, weight and FPG increased (p


Related Articles

  • Rosiglitazone. Barman Balfour, J.A.; Plosker, G.L. // Drugs;Jun1999, Vol. 57 Issue 6, p921 

    â–´ Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. â–´ In animal models of insulin resistance, rosiglitazone decreased plasma glucose,...

  • Effects of Short-Term Metformin Pretreatment.  // Fertility Weekly;11/16/2009, p3 

    The article reports on a study that investigates the effects of short-term metformin pretreatment of women with polycystic ovary syndrome (PCOS). It notes that the short-course pretreatment with metformin decreased the hyperandrogenism and insulin resistance of the patient. Moreover, it improved...

  • The Effect of Alogliptin and Metformin Combination Therapy in Type 2 Diabetes: A Pilot Study. Kishimoto, Miyako; Inoue, Kaori; Noda, Mitsuhiko // Journal of Endocrinology & Metabolism;2013, Vol. 3 Issue 4/5, p111 

    Background: As type 2 diabetes is characterized by both insulin resistance and impaired insulin secretion, oral anti-diabetic treatments including dipeptidyl peptidase-4 inhibitors, which stimulate insulin secretion, and biguanides, which enhance insulin sensitivity should be considered....

  • Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. Hettihewa, L. M.; Jayasinghe, S. S.; Imendra, K. G.; Weerarathna, T. P. // International Journal of Diabetes in Developing Countries;Jan-Mar2008, Vol. 28 Issue 1, p26 

    OBJECTIVE: To examine effects of pioglitazone (PIO) on systolic, diastolic, pulse and mean blood pressures (SBP, DBP, PP and MP, respectively) in type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: One hundred and six normotensive patients with T2DM with mean fasting blood glucose (FBS; 183...

  • Effects of Metformin on Lipid Profile and Insulin Resistance.  // Fertility Weekly;3/10/2008, p9 

    The article reports on the result of the study conducted by M. A. Karimzadeh and colleagues which evaluates the effects of metformin on lipid profile, insulin resistance, body mass index in women with polycystic ovary syndrome (PCOS). Results reveal that metformin causes an increase in ovulation...

  • Metformin Augments Levels of Molecules that Regulate GLUT4 in Endometria.  // Fertility Weekly;1/6/2014, p5 

    The article presents a study to find whether the metabolic-endocrine hyperinsulinemic polycystic ovary syndrome (PCOS-h-INS) in women, can be controlled with alterations in the molecule levels of proteins that regulate expression of insulin-dependent glucose transporter (GLUT4). Metformin...

  • Renoprotective Effect of Metformin. Ahmadi, Farrokhlagha; Mohebi-Nejad, Azin // Iranian Journal of Kidney Diseases;Nov2013, Vol. 7 Issue 6, p417 

    The authors discuss the benefits and renoprotective effect of metformin for glycemic control and cardiovascular complications in diabetic patients. They explore studies that reveal the effect of metformin in gentamicin nephtotoxicity and reactive oxygen species (ROS). The authors agree that...

  • Diabetes and Cancer-Related Mechanisms. Vinall, Maria // MD Conference Express;Dec2011, p25 

    The article discusses the relationship between cancer and diabetes, and the effect of potential therapies on cancer risk in diabetic patients. It suggests that increased lowgrade pancreatic inflammation is a potential factor in the generation of cancer in diabetes and obesity. Doctor Edwin Gale...

  • Metabolic Syndrome and Neurotrophins: Effects of Metformin and Non-Steroidal Antiinflammatory Drug Treatment. Hristova, Mariyana G. // Eurasian Journal of Medicine;Dec2011, Vol. 43 Issue 3, p141 

    Objective: Metabolic syndrome (MS) presents with central obesity, impaired glucose metabolism, dyslipidemia and hypertension. Our aim was to examine the effect of metformin treatment either alone or in combination with non-steroidal anti-inflammatory drugs (NSAID) on plasma levels of nerve...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics